The last few years have seen great progress be made in molecular diagnostic tools, allowing us to gain new perspectives on disease biology. It also explains why different people react to the same stages of the disease in different ways. Despite the fact that cancer classifications have evolved significantly in recent years, it was Perou et al.'s molecular classification of breast cancer that revolutionized the face of contemporary oncology. Instead, the focus is now on identifying molecular signatures of distinct tumors which are used to discover specific mutations that might be used as prognostic indicators, and therapeutic targets for different medications. The novel targets will also spur research into developing more targeted treatments. In light of this, we'd like to ask a number of experts in various solid organ tumors to share their perspectives.
The goal is to classify all solid organ cancers based on their molecular signatures available in the present literature. This would also act as a surrogate in identifying new targets that may be used for future pharmacological therapies. Improved molecular classification of solid tumors are important for the identification of biomarkers, which will enable us to better understand the molecular mechanisms of the tumor, type- specific survival, drug resistance, relapse and patient outcomes in a highly individualized manner.
We invite experts to submit manuscripts to this Research Topic concerning the description of molecular classification and/or potential therapeutic targets in solid organ cancers. Each of the manuscripts will then be peer reviewed and followed up as per Frontiers in Oncology’s protocol.
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
The last few years have seen great progress be made in molecular diagnostic tools, allowing us to gain new perspectives on disease biology. It also explains why different people react to the same stages of the disease in different ways. Despite the fact that cancer classifications have evolved significantly in recent years, it was Perou et al.'s molecular classification of breast cancer that revolutionized the face of contemporary oncology. Instead, the focus is now on identifying molecular signatures of distinct tumors which are used to discover specific mutations that might be used as prognostic indicators, and therapeutic targets for different medications. The novel targets will also spur research into developing more targeted treatments. In light of this, we'd like to ask a number of experts in various solid organ tumors to share their perspectives.
The goal is to classify all solid organ cancers based on their molecular signatures available in the present literature. This would also act as a surrogate in identifying new targets that may be used for future pharmacological therapies. Improved molecular classification of solid tumors are important for the identification of biomarkers, which will enable us to better understand the molecular mechanisms of the tumor, type- specific survival, drug resistance, relapse and patient outcomes in a highly individualized manner.
We invite experts to submit manuscripts to this Research Topic concerning the description of molecular classification and/or potential therapeutic targets in solid organ cancers. Each of the manuscripts will then be peer reviewed and followed up as per Frontiers in Oncology’s protocol.
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
